Relapsed/Refractory Follicular Lymphoma: Future Directions in Care

Transcript:

Sameh R. Gaballa, MD: To wrap up, Dr. Lunning, what has been your real-life experience with these patients with POD24 [progression of disease within 24 months]—do you recommend CAR T or bispecifics or transplant for those high-risk patients?

Matthew A. Lunning, DO, FACP: Yeah, I think that it’s about sequencing and putting the best therapy that you think is going to be impactful to changing the paradigm of their disease. Because you don’t know about it when you’re first treating them. You only find out about POD24 within 24 months after the start of their therapy. That’s where you have to be very strategic. Right now with all of the therapies we have, I don’t know that they’re mutually exclusive. That one is going to rule out the other, so I have been thinking that bispecifics may come before CAR T in this scenario. I still think that lenalidomide could potentially come before bispecifics. I think there is some data to show that with R-squared you can get longer therapy or duration of responses than you did with the first line. And so, in a person [with whom] you’re trying to plan for decades, not for 2 years, of further of their life, like the case you described, the 53-year-old, you want to get them into their seventh decade of life. That’s part of the discussion. I’m laying out the table and playing the chess match against their disease. I don’t think that you always have to play the same piece all the time. Each patient has to understand the risk and the benefits of what you’re doing.

Sameh R. Gaballa, MD: No, no, that’s great. Well, thank you so much, Dr. Lunning, for this very insightful discussion. To our viewing audience, thank you for joining us today. We hope you found this OncLive® My Treatment Approach program to be useful and valuable to the management of your patients with follicular lymphoma. Thank you very much.

Transcript edited for clarity.